Stock PANG PANGAEA ONCOLOGY, S.A.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Pangaea Oncology, S.A.

Equities

PANG

ES0105221008

Market Closed - BME
Other stock markets
 10:00:07 2024-07-17 am EDT 		5-day change 1st Jan Change
1.77 EUR +1.14% Intraday chart for Pangaea Oncology, S.A. +4.12% -3.80%
May. 08 Pangaea Oncology, S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 Pangaea Oncology, S.A. Reports Earnings Results for the Half Year Ended June 30, 2023 CI

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.
  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

  • According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.

Weaknesses

  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • The company has insufficient levels of profitability.
  • The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
  • The company's enterprise value to sales, at 4.26 times its current sales, is high.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
  • The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
PANGAEA ONCOLOGY, S.A. Stock Pangaea Oncology, S.A.
-3.80% 58.34M -
MODERNA, INC. Stock Moderna, Inc.
+24.74% 47.54B
B-
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-0.47% 41.96B
B
LONZA GROUP AG Stock Lonza Group AG
+43.96% 41.55B
A
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
+25.40% 30.36B
B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+17.96% 27.61B
B-
CELLTRION, INC. Stock Celltrion, Inc.
-4.47% 28.7B
C
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+50.73% 14.7B
B+
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+42.56% 13.51B
C+
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+1.46% 12.34B
B+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
-
4m Target Price Revision
-
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. PANG Stock
  4. Ratings Pangaea Oncology, S.A.